fbpx
Register Log-in Investor Type

News

North Atlantic Smaller Companies 2022 results

North Atlantic Smaller Companies delivered an NAV return of 9.2% over the year ended 31 January 2022. The chairman notes that this compares with a rise in the sterling adjusted Standard & Poors Composite Index of 24.0%. The Standard and Poors Composite Index was, however, not representative of the US market in general; for example, the Russell Index of Smaller Companies actually fell during the period. However, the company materially outperformed a number of more comparable UK indices where most of the investment assets are quoted. There is no dividend this year.

Extract from the manager’s report

quoted portfolio UK
Once again the year was one of two halves. Our life science businesses performed extremely well in the first half but suffered towards the year end due to the derating of growth stocks in the United States and concerns about “COVID” stocks in the United Kingdom as the threat of the pandemic subsides. Ironically, our two “COVID” companies never achieved silly valuations unlike many others which never had any earnings in the first place. Following the derating it is our opinion that both EKF and SourceBio International are materially undervalued and this will become increasingly apparent as their core business continues to experience good growth over the next few years.

Polar Capital a fund management business which has significant exposure to high technology in the USA and Gleeson which is in the firing line to contribute to the cladding crisis have both fallen in recent months but we are confident that these are both high quality businesses that will prosper over the medium term.

The balance of the portfolio generally performed well with notable successes in Assetco, Augean, Frenkel Topping, Hargreaves Services, Signature (which was taken over) Sureserve and Ten Entertainment.

Finally, it is encouraging to note that both Oryx International Growth Fund Limited and Odyssean Investment Trust Plc, beat their respective benchmarks.

quoted portfolio USA
The performance of this small portfolio was satisfactorily led by the largest holding Mountain Commerce which rose over 50% during the twelve month period to 31 January 2022.

unquoted portfolio UK
The UK portfolio benefitted from bids for Pelsis (Hamsard 3468), Viking and Antler Holdco all at significant premiums to the valuation at 31 January 2021. Trellus also went public at a significant premium to 31 January 2021 valuation.

Despite continuing difficulties in the supply chain, Specialist Components saw strong recovery in its business operations which gives us encouragement that the company will flourish as economic activity returns to some degree of normality. Spring Investments, on the other hand, continued to underperform and was marked down during the period.

unquoted portfolio USA
Utitec had a good year and the prospects for 2022 are good. The company is now in the process of being sold which, if successful, will result in an uplift in the current value and a return of capital for the company of over £10 million (including the indirect investment via Trident Private Equity III).

Performance Chemicals successfully won a lawsuit against former employees who had infringed its patents. This resulted in a significant return of capital (in reality 100% of our actual investment). The outlook is currently promising and we intend to seek investor liquidity over the next eighteen months.

Jaguar had a good year despite continuing problems in the airline industry. As a consequence, the business is expected to return 20% of our actual investment in the near term. Shareholder liquidity will be sought when industry conditions return to some degree of normality.

Coventbridge is also preparing itself for a liquidity event at the end of the current year which should result in a further £20 million of liquidity for the Company (including the indirect investment via Harwood Private Equity IV).

Finally, the sale of Utitec will effectively mean the liquidation of Trident Private Equity III. Exposure to Harwood Private Equity IV will decline as Journey releases cash and Coventbridge is sold. We are very excited about Harwood Private Equity V not least because a recent investment was sold at over 250% of cost.

NAS : North Atlantic Smaller Companies 2022 results

previous story | next story

Leave a Reply

Your email address will not be published. Required fields are marked *

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…